Ensysce Biosciences, Inc.ENSCNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +685.26% | +153.12% | +331.76% | +654.38% | -85.58% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | -242.45% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -97.25% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -680.24% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -663.51% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -229.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -229.00% |
| Weighted Average Shares Growth | -35.03% | -45.72% | +269.08% | +9.84% | +43.94% |
| Weighted Average Shares Diluted Growth | -78.63% | -45.72% | +269.04% | +9.84% | +337.71% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1554.76% | +27.22% | -77.14% | +437.40% | -99.75% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +191.57% | +106.69% | -9.11% | +99.40% | -66.12% |
| Book Value per Share Growth | +615.96% | +0.00% | -77.97% | +70.67% | -87.90% |
| Debt Growth | +9.48% | -64.71% | +4.64% | -6.59% | -5.97% |
| R&D Expense Growth | -11.70% | +70.31% | +142.14% | +103.06% | +74.74% |
| SG&A Expenses Growth | -11.79% | -25.07% | +2.34% | +0.72% | +18.12% |